Concepedia

A phase II study of lapatinib, a dual EGFR and HER-2 tyrosine kinase inhibitor, in patients with castration-resistant prostate cancer

Young E. Whang, Andrew J. Armstrong, W. Kimryn Rathmell, Paul A. Godley, William Y. Kim, Raj S. Pruthi, Eric Wallen, Jeffrey M. Crane, Dominic T. Moore, Gayle Grigson,

Urologic Oncology Seminars and Original Investigations · 2011 · 85 citations · 29 references

DOI

Concepts

References

29

New Guidelines to Evaluate the Response to Treatment in Solid Tumors

Patrick Therasse, Susan G. Arbuck, Elizabeth A. Eisenhauer et al. · JNCI Journal of the National Cancer Institute · 2000 · 15.7K citations

, , +17

Docetaxel plus Prednisone or Mitoxantrone plus Prednisone for Advanced Prostate Cancer

Ian F. Tannock, Ronald de Wit, William R. Berry et al. · New England Journal of Medicine · 2004 · 5.7K citations

Docetaxel and Estramustine Compared with Mitoxantrone and Prednisone for Advanced Refractory Prostate Cancer

Daniel P. Petrylak, Catherine M. Tangen, Maha Hussain et al. · New England Journal of Medicine · 2004 · 3.7K citations · Full text

Design and End Points of Clinical Trials for Patients With Progressive Prostate Cancer and Castrate Levels of Testosterone: Recommendations of the Prostate Cancer Clinical Trials Working Group

Howard I. Scher, Susan Halabi, Ian F. Tannock et al. · Journal of Clinical Oncology · 2008 · 2.2K citations · Full text

A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signaling by the HER-2/neu tyrosine kinase

Noah Craft, Yuriy Shostak, Michael Carey et al. · Nature Medicine · 1999 · 983 citations

, , +9